Recent Quotes (30 days)

You have no recent quotes
chg | %

Shire PLC news

   Watch this stock
Showing stories 1 - 10 of about 125   

Articles published

SHP 4,852.00 -47.00 (-0.96%)
price chart
Could SkyePharma PLC Outperform Shire PLC And Hikma Pharmaceuticals Plc?
Shares in small-cap pharmaceutical firm SkyePharma (LSE: SKP) popped 5% higher this morning, after the firm said that sales had risen by 19% during the first half of 2015 and that underlying trading for 2015 is expected to be “ahead of previous ...
Large Inflow of Money Witnessed in Shire plc
Shire plc (NASDAQ:SHPG) dropped by -0.85 or -1.93 points during the last session to $224.47 per share. One of the highlights of the day was the net money flow figure, which stood at $0.4 million even as the stock accepted $15.9 million in upticks but ...
Shire plc Price Target Update  American Trade Journal
Why I'd Buy Hikma Pharmaceuticals Plc, Hold Shire plc & Sell AstraZeneca plc
Shire is the best of all based on fundamentals, but its stock carries more risk now than at any given time this year. Its latest deal-making ambitions will be debated for months, and Baxalta could be a pricey target - there is a significant risk that ...
Shire PLC Receives Average Rating of "Buy" from Brokerages (LON:SHP)
Shire PLC logo Shire PLC (LON:SHP) has received an average recommendation of “Buy” from the nineteen ratings firms that are currently covering the stock, MarketBeat reports.
Sanford C. Bernstein Reiterates "Outperform" Rating for Shire PLC ...  WKRB News
Shire PLC Given Neutral Rating at BNP Paribas (SHP)  Financial Wisdom Works
Why Shire plc & Royal Bank Of Scotland Group plc Could Plunge Much Further
Shire (LSE: SHP) stock was a pretty straightforward investment until Tuesday 4 August, but has become a less obvious call following the British group's hostile approach for US biotech rival Baxalta, which values the target at $30bn.
As AstraZeneca plc Slumps, Should You Sell And Buy Shire PLC?
Shire's growth is exploding, and investors are clamouring to get their hands on the company's shares. Excluding exceptional items, the company delivered earnings growth of 38% last year.
Shire PLC Stock Rating Reaffirmed by Sanford C. Bernstein (SHP)
Shire PLC logo Shire PLC (LON:SHP)'s stock had its “outperform” rating restated by Sanford C. Bernstein in a note issued to investors on Thursday, Market Beat reports.
Shire PLC to Issue Dividend of GBX 2.69 on October 2nd (SHP)  Financial Wisdom Works
Insider Buying: Manchester & London Investment Trust plc insider ...  The Legacy
Which is Your Best Pharma Bet: GlaxoSmithKline plc, AstraZeneca plc Or Shire PLC?
The mantra of expand and diversify seems to have gone rather out of fashion since the global financial crisis and recession. These days the rallying cry is: concentration and focus.
Pharma Showdown: Should You Buy GlaxoSmithKline plc Or Shire PLC?
If you're struggling to choose between GlaxoSmithKline (LSE: GSK) and Shire (LSE: SHP), you're not alone. Glaxo and Shire are two of the UK's premier pharmaceutical companies, with their individual strengths and weaknesses. And choosing between the ...
Will Shire PLC (ADR) Sweeten Its Takeover Offer For Baxalta Inc?
Shire Plc (ADR) (NASDAQ:SHPG) is currently hard at work trying to woo Baxalta Inc. (NYSE:BXLT) into selling its business. Shire publicly announced its interest in the company on August 4, offering approximately $30 billion for the acquisition.
Baxalta Said to Abandon Takeover Talks With Drugmaker Ariad  Bloomberg
Ariad shares fall 17% on Baxalta report  Boston Globe